Purpose To review published data pertaining to the clinical experience with a
dexamethasone intravitreal implant (Ozurdex®) with a view to establishing a clinically based …

Objective To compare the efficacy and safety of intravitreal dexamethasone (DEX) implant
and anti-vascular endothelial growth factor (anti-VEGF) agents in the treatment of macular …

Purpose The purpose of this study was to determine the clinical efficacy of low-frequency
intravitreal ranibizumab to treat macular edema due to retinal vein occlusion (RVO). Patients …

Purpose. To evaluate whether treatment with intravitreal corticosteroid and anti‐vascular
endothelial growth factor (VEGF) injections alternately can improve treatment outcomes of …

Background The aim was to make a real‐world comparison of the efficacy of ranibizumab,
dexamethasone and grid laser treatments in macular oedema due to branch retinal vein …

Introduction: The role of vascular endothelial growth factor in macular edema (ME) due to
branch retinal vein occlusion (BRVO) by enhancing vascular permeability has been well …

Purpose The purpose of this study was to determine the short-term outcomes for patients
who received intravitreal aflibercept (IVA) with or without intravitreal ranibizumab (IVR) for …

PURPOSE The aim of this study was to compare the 2-year real-world outcomes of
intravitreal ranibizumab with dexamethasone implants in patients with macular edema …

Purpose To assess and compare the efficacy over 6 months of intravitreal ranibizumab (IR),
aflibercept (IA) and dexamethasone implant (IDI) in eyes with macular edema (ME) …

Aim: The aim of this study was to compare early and late injections of intravitreal
dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or …